PepGen Inc. (PEPG)
Market Cap | 529.05M |
Revenue (ttm) | n/a |
Net Income (ttm) | -80.33M |
Shares Out | 32.42M |
EPS (ttm) | -3.24 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 82,863 |
Open | 18.04 |
Previous Close | 17.91 |
Day's Range | 16.31 - 18.04 |
52-Week Range | 3.72 - 18.72 |
Beta | 1.77 |
Analysts | Strong Buy |
Price Target | 23.00 (+40.93%) |
Earnings Date | Aug 6, 2024 |
About PEPG
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-ED... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for PEPG stock is "Strong Buy." The 12-month stock price forecast is $23.0, which is an increase of 40.93% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/q/z/press4-2472899.jpg)
PepGen Announces Executive Team Promotions
BOSTON--(BUSINESS WIRE)--This is an appointment release for PepGen. They are announcing 2 promotions on their team.
![](https://cdn.snapi.dev/images/v1/7/v/press15-2430611.jpg)
PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
– CONNECT1-EDO51 trial preliminary data from 5mg/kg dose cohort expected mid-2024 – – FREEDOM1-DM1 trial preliminary data from at least 5mg/kg dose cohort expected second half 2024 – – N et proceeds o...
![](https://cdn.snapi.dev/images/v1/g/r/conf19-2323073.jpg)
PepGen to Participate in Upcoming Investor Conferences
BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming t...
![](https://cdn.snapi.dev/images/v1/i/a/press19-2321775.jpg)
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming t...
![](https://cdn.snapi.dev/images/v1/n/k/press18-2311801.jpg)
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
- Enrollment completed for PGN-EDO51 5 mg/kg cohort in CONNECT1-EDO51 Phase 2 clinical trial in DMD patients. The Company expects to announce preliminary data from the 5 mg/kg dose cohort in mid-2024 ...
![](https://cdn.snapi.dev/images/v1/p/r/press20-2305859.jpg)
PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
BOSTON, March 04, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming t...
![](https://cdn.snapi.dev/images/v1/x/q/press2-2283292.jpg)
PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1
BOSTON, Feb. 20, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming th...
![](https://cdn.snapi.dev/images/v1/u/m/press7-2264157.jpg)
PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock
BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming th...
![](https://cdn.snapi.dev/images/v1/w/k/press20-2232100.jpg)
Mary Beth DeLena Joins PepGen as General Counsel and Secretary
BOSTON, Jan. 17, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming th...
![](https://cdn.snapi.dev/images/v1/e/h/press9-2219824.jpg)
PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping
- Preliminary data from the 5 mg/kg PGN-EDO51 dose level in the CONNECT1-EDO51 Phase 2 trial are expected mid-2024: including initial safety, exon 51 skipping and dystrophin protein production data -
![](https://cdn.snapi.dev/images/v1/w/h/press4-2199878.jpg)
PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
- Safety, transcript splicing correction and clinical outcome measures data at 5 mg/kg PGN-EDODM1 dose level in patients from FREEDOM-DM1 clinical trial expected in 2024 -
![](https://cdn.snapi.dev/images/v1/k/n/press2-2159060.jpg)
PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors
BOSTON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming th...
![](https://cdn.snapi.dev/images/v1/q/k/press13-2146622.jpg)
PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
- Continuing to open CONNECT1-EDO51 trial sites in Canada - - Opening of FREEDOM-DM1 trial sites underway in the U.S. and Canada - - Ended third quarter 2023 with cash and cash equivalents of $129.5 m...
![](https://cdn.snapi.dev/images/v1/q/x/press15-2100277.jpg)
PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
– Lifting of FDA hold allows FREEDOM-DM1 study to launch in the U.S. with target dose levels of 5 mg/kg, 10 mg/kg and 20 mg/kg –
![](https://cdn.snapi.dev/images/v1/0/c/press10-2080730.jpg)
PepGen Announces Upcoming Presentations at the 28th Annual Congress of the World Muscle Society and the World Congress of Neurology
BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming t...
![](https://cdn.snapi.dev/images/v1/c/w/press16-2052412.jpg)
PepGen Inc. Announces Clearance of CTA by Health Canada to Begin the FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 in Patients with Myotonic Dystrophy Type 1
The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to PGN-EDODM1 for the treatment of Myotonic Dystrophy Type 1 (DM1) The U.S. Food and Drug Administration (FDA) granted Orpha...
![](https://cdn.snapi.dev/images/v1/s/s/press15-2051113.jpg)
PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Company's Enhanced Delivery Oligonucleotide Platform and PGN-EDODM1 Program at Two Medical Conferences
- EDO platform observed to drive 25-fold higher level of oligonucleotide delivery to myotube nuclei compared to “naked” oligonucleotide -
![](https://cdn.snapi.dev/images/v1/h/c/conf2-2046479.jpg)
PepGen Announces Presentations at the 2023 Myotonic Dystrophy Foundation Annual Conference, Ottawa Neuromuscular Disease Meeting, and H.C. Wainwright 25th Annual Global Investment Conference
BOSTON, Sept. 01, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming t...
![](https://cdn.snapi.dev/images/v1/j/i/press18-2011769.jpg)
PepGen Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
– Phase 2 open-label CONNECT1-EDO51 study open in Canada – – Potentially registrational, randomized, double-blind, placebo-controlled Phase 2 CONNECT2-EDO51 multinational study expected to be initiate...
![](https://cdn.snapi.dev/images/v1/u/p/press3-1932683.jpg)
PepGen Inc. Provides Update on Planned Initiation of Phase 1 Study of PGN-EDODM1 in Myotonic Dystrophy Type 1
BOSTON, June 13, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming th...
![](https://cdn.snapi.dev/images/v1/v/r/press7-1912997.jpg)
PepGen Inc. Announces Clinical Hold in the U.S. on IND Application to Initiate a Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the...
![](https://cdn.snapi.dev/images/v1/s/c/press14-1896795.jpg)
PepGen Announces Clearance by Health Canada of CTA for PGN-EDO51 to Begin the Phase 2 Clinical Trial, CONNECT1-EDO51, for the Treatment of Duchenne Muscular Dystrophy
- CONNECT1-EDO51 will assess dystrophin levels, exon skipping data and safety data following multiple doses of PGN-EDO51 in patients with mutations amenable to skipping exon 51 -
![](https://cdn.snapi.dev/images/v1/f/h/press6-1884602.jpg)
PepGen Reports First Quarter 2023 Financial Results and Recent Corporate Developments
– Phase 2 open-label CONNECT1-EDO51 study expected to be initiated in Canada in the first half of 2023 – – Potentially registration-directed, randomized, double-blind, placebo-controlled Phase 2 CONNE...
![](https://cdn.snapi.dev/images/v1/d/i/press9-1871215.jpg)
PepGen to Participate in the Bank of America Securities 2023 Healthcare Conference
BOSTON, May 04, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the...
![](https://cdn.snapi.dev/images/v1/a/k/press12-1839298.jpg)
PepGen Announces Upcoming Data Presentations at the 2023 American Academy of Neurology Annual Meeting
BOSTON, April 17, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming t...